These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 7919566)

  • 21. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study.
    Gauthier S; Bouchard R; Lamontagne A; Bailey P; Bergman H; Ratner J; Tesfaye Y; Saint-Martin M; Bacher Y; Carrier L
    N Engl J Med; 1990 May; 322(18):1272-6. PubMed ID: 2183056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration.
    Qizilbash N; Whitehead A; Higgins J; Wilcock G; Schneider L; Farlow M
    JAMA; 1998 Nov; 280(20):1777-82. PubMed ID: 9842955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease.
    Molloy DW; Guyatt GH; Wilson DB; Duke R; Rees L; Singer J
    CMAJ; 1991 Jan; 144(1):29-34. PubMed ID: 1984813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
    Antuono PG
    Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of the randomized controlled trials of tacrine in the treatment of Alzheimer's disease: methodologic considerations.
    Conway EL
    Clin Neuropharmacol; 1998; 21(1):8-17. PubMed ID: 9579280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacokinetics of tacrine.
    Madden S; Spaldin V; Park BK
    Clin Pharmacokinet; 1995 Jun; 28(6):449-57. PubMed ID: 7656503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (Cognex) in Alzheimer's patients.
    Smith F
    J Biopharm Stat; 1996 Mar; 6(1):59-67. PubMed ID: 8838779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Tacrine].
    Dávila C; Viteri C; de Castro P
    Rev Med Univ Navarra; 1997; 41(1):58-64. PubMed ID: 9527715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease.
    Schneider LS; Farlow MR; Henderson VW; Pogoda JM
    Neurology; 1996 Jun; 46(6):1580-4. PubMed ID: 8649552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tacrine. Alzheimer's disease and the cholinergic theory. A critical review and results of a new therapy.
    Boller F; Orgogozo JM
    Neurologia; 1995 May; 10(5):194-9. PubMed ID: 7619536
    [No Abstract]   [Full Text] [Related]  

  • 31. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease.
    Schneider LS; Olin JT; Pawluczyk S
    Am J Psychiatry; 1993 Feb; 150(2):321-3. PubMed ID: 8422085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Balance sheet of tolerance-efficacy on the use of tacrine in 100 cases of Alzheimer's disease].
    Estadieu MC; Machou C; Berthezène P; Pastor MJ; Angelini B; Bohor M; Bongrand MC; Timon-David P; Gastaut JL; Allain H; Michel BF
    Therapie; 1998; 53(1):67-76. PubMed ID: 9773102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of tacrine: clinical trials, treatment IND, and postmarketing experience.
    Gracon SI; Knapp MJ; Berghoff WG; Pierce M; DeJong R; Lobbestael SJ; Symons J; Dombey SL; Luscombe FA; Kraemer D
    Alzheimer Dis Assoc Disord; 1998 Jun; 12(2):93-101. PubMed ID: 9651138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic approaches to cognitive deficits in Alzheimer's disease.
    Peskind ER
    J Clin Psychiatry; 1998; 59 Suppl 9():22-7. PubMed ID: 9720483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration.
    Burback D; Molnar FJ; St John P; Man-Son-Hing M
    Dement Geriatr Cogn Disord; 1999; 10(6):534-40. PubMed ID: 10559571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.
    Holford NH; Peace KE
    Proc Natl Acad Sci U S A; 1992 Dec; 89(23):11466-70. PubMed ID: 1454835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tacrine treatment of Alzheimer's disease: many expectations, few certainties.
    Malaguarnera M; Pistone G; Vinci M; Motta M; di Fazio I; Rampello L
    Neuropsychobiology; 1998 Nov; 38(4):226-31. PubMed ID: 9813462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of survival analysis techniques in evaluating the effect of long-term tacrine (Cognex) treatment on nursing home placement and mortality in patients with Alzheimer's disease.
    Smith F; Talwalker S; Gracon S; Srirama M
    J Biopharm Stat; 1996 Nov; 6(4):395-409. PubMed ID: 8969976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of the value of therapeutic monitoring of tacrine in Alzheimer's disease.
    Roberts CJ; Ford JM; Truman CA; Scott M; Mäkelä PM; Wilcock GK
    Eur J Clin Pharmacol; 1998; 54(9-10):721-4. PubMed ID: 9923574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A double-blind, placebo-controlled study of tacrine in Chinese patients with Alzheimer's disease.
    Wong WJ; Liu HC; Fuh JL; Wang SJ; Hsu LC; Wang PN; Sheng WY
    Dement Geriatr Cogn Disord; 1999; 10(4):289-94. PubMed ID: 10364647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.